ImmunoGen, Inc. (IMGN) Receives Consensus Rating of “Hold” from Brokerages
Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have earned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.30.
IMGN has been the subject of a number of research analyst reports. ValuEngine downgraded ImmunoGen from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 price target on shares of ImmunoGen in a research report on Monday, September 25th. Jefferies Group reiterated a “buy” rating and set a $9.00 price target on shares of ImmunoGen in a research report on Thursday, October 12th. Finally, Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, October 31st.
Shares of ImmunoGen (IMGN) opened at $7.40 on Wednesday. The stock has a market capitalization of $1,150.00, a PE ratio of -5.69 and a beta of 2.20. The company has a current ratio of 2.81, a quick ratio of 2.78 and a debt-to-equity ratio of -0.03. ImmunoGen has a 12-month low of $2.20 and a 12-month high of $8.84.
A number of large investors have recently added to or reduced their stakes in IMGN. Arrowstreet Capital Limited Partnership bought a new stake in ImmunoGen in the 2nd quarter worth approximately $102,000. Intl Fcstone Inc. bought a new stake in ImmunoGen in the 2nd quarter worth approximately $115,000. Raymond James Financial Services Advisors Inc. bought a new stake in ImmunoGen in the 2nd quarter worth approximately $126,000. Virginia Retirement Systems ET AL bought a new stake in ImmunoGen in the 3rd quarter worth approximately $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in ImmunoGen in the 3rd quarter worth approximately $143,000. Institutional investors own 68.02% of the company’s stock.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.